Patent application number | Description | Published |
20110153340 | SPEND DIAGNOSTICS AND LEAD MANAGEMENT - A method and system are used to optimize utilization of a transaction card by a card member. The system and method including generating a first data set based on data stored in a database representing industries of the card members. Generating a second data set representing an average amount charged to a transaction account by the card members in each respective one of the industries based on the first data set. Comparing the average amount charged from the first generating step to an actual amount charged by each individual one of the card members in a respective one of the industries. Communicating a result of the comparison to the card members. Receiving data from the card members based on their receiving of the comparison result. Storing the data in the database or a lead management device, such that the data is updated. | 06-23-2011 |
20110202386 | IDENTIFYING INDUSTRY SEGMENTS WITH HIGHEST POTENTIAL FOR NEW CUSTOMERS OR NEW SPENDING FOR CURRENT CUSTOMERS - A method and system are used to identify industry segments with highest potential for new customers or new spending for current customers. This includes receiving data, segregated into each of a plurality of industries, relating to a number of small businesses, cost of goods sold for each of the small businesses, and percentage of cost of goods sold that is spent on raw materials and inventory for each of the small businesses. Capturing data, segregated into each of the plurality of industries, relating to average amount charged per current card member, percentage of the current card members charging the raw materials and the inventory, percentage of card member penetration, and total estimated charging for the current card members. Determining which of the plurality of industries or segments of the plurality of the industries are available for a highest potential for new card members or that are available for a greatest amount of incremental increased charging by the current card members. Communicating with the current card members in each of the plurality of industries or segments and receiving data therefrom based on one or more of the previous steps. Communicating with internal and external sources to capture additional industry-specific charging data. Receiving data relating to industry reports and census data. Generating ranked data sets based on the previous steps. | 08-18-2011 |
20120203593 | SPEND DIAGNOSTICS AND LEAD MANAGEMENT - A method and system are used to optimize utilization of a transaction card by a card member. The system and method including generating a first data set based on data stored in a database representing industries of the card members. Generating a second data set representing an average amount charged to a transaction account by the card members in each respective one of the industries based on the first data set. Comparing the average amount charged from the first generating step to an actual amount charged by each individual one of the card members in a respective one of the industries. Communicating a result of the comparison to the card members. Receiving data from the card members based on their receiving of the comparison result. Storing the data in the database or a lead management device, such that the data is updated. | 08-09-2012 |
20120290357 | IDENTIFYING INDUSTRY SEGMENTS WITH HIGHEST POTENTIAL FOR NEW CUSTOMERS OR NEW SPENDING FOR CURRENT CUSTOMERS - A method and system are used to identify industry segments with highest potential for new customers or new spending for current customers. This includes receiving data, segregated into each of a plurality of industries, relating to a number of small businesses, cost of goods sold for each of the small businesses, and percentage of cost of goods sold that is spent on raw materials and inventory for each of the small businesses. Capturing data, segregated into each of the plurality of industries, relating to average amount charged per current card member, percentage of the current card members charging the raw materials and the inventory, percentage of card member penetration, and total estimated charging for the current card members. Determining which of the plurality of industries or segments are available for a highest potential for new card members. | 11-15-2012 |
Patent application number | Description | Published |
20110191282 | Evaluating Statistical Significance Of Test Statistics Using Placebo Actions - Methods, systems, and apparatus, including computer programs encoded on computer storage media, for evaluating statistical significance using placebo actions. One method includes receiving exposure data and control data describing exposed and control subjects and determining a test statistic for each of a plurality of subject actions including a desired action and a plurality of placebo actions. The test statistic for an action corresponds to an estimated effect that exposure to the treatment has on a likelihood that a subject will take the action. The method further includes comparing the test statistic for the desired action to the test statistics for the plurality of placebo actions, and determining whether the test statistic for the desired action is statistically significant according to the comparison. Another method includes automatically identifying placebo actions using a taxonomy that classifies subject actions or treatments, and determining test statistics for the placebo actions. | 08-04-2011 |
20120084125 | Search Change Model - Systems, methods and computer program products for determining lost opportunities resulting from changes to advertising spending are described. To assist advertisers in evaluating and allocating a proper budget to advertising, an analyzer can be used to develop an analytical model that gathers data pertaining to the incremental value of search advertising. (e.g., the true cost of the additional click lost or gained), which can be presented to the advertisers when changes have been made/proposed to the advertiser's advertising spending. The analyzer can detect large changes in advertising spending, and indicate (e.g., by prediction) how many total clicks were lost or gained as a result of the change in advertising spending to allow the advertisers to visualize the impact to changes in advertising spending, and determine when to decrease advertising budget on ads that yield low return-on-investment or to increase advertising budget to maximize the effectiveness of an active ad campaign. | 04-05-2012 |
Patent application number | Description | Published |
20120220973 | ADHESIVE BANDAGE - Adhesive bandages having a backing layer with first and second opposing surfaces, and an absorbent pad associated with the backing layer, the absorbent pad including a first surface that faces the second surface of the backing layer and an opposing second surface having a plurality of tufted regions surrounded and separated by a first network of interconnecting channels recessed in the second surface of the absorbent pad; where the tufted regions have a substantially uniform first density, the channel base region has a substantially uniform second density that is greater than the substantially uniform first density of the tufted regions and the network of channels is visible. | 08-30-2012 |
20120220974 | ADHESIVE BANDAGE - Adhesive bandages having a backing layer with first and second opposing surfaces, an adhesive layer applied to the second surface of the backing layer and an absorbent pad associated with the backing layer, the absorbent pad including a first surface that faces the second surface of the backing layer and an opposing second surface having a plurality of tufted regions surrounded and separated by a first network of interconnecting channels recessed in the second surface of the absorbent pad; where the shape of the tufted regions is a polygon having from five to eight sides, the tufted regions have a substantially uniform first density, the channel base region has a substantially uniform second density that is greater than the substantially uniform first density of the tufted regions and the network of channels is visible. | 08-30-2012 |
20120220975 | ADHESIVE BANDAGE - Adhesive bandages having a backing layer with first and second opposing surfaces, an adhesive layer applied to the second surface of the backing layer and an absorbent pad associated with the backing layer, the absorbent pad including a first surface that faces the second surface of the backing layer and an opposing second surface having a plurality of tufted regions surrounded and separated by a first network of interconnecting channels recessed in the second surface of the absorbent pad; where the shape of the tufted regions is a polygon having from five to eight sides, the tufted regions have a substantially uniform first density, the channel base region has a substantially uniform second density that is greater than the substantially uniform first density of the tufted regions and the network of channels is visible. | 08-30-2012 |
Patent application number | Description | Published |
20080214553 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists - The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression. | 09-04-2008 |
20090264416 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES - The present invention relates to N-benzyl,N′-arylcarbonylpiperazine derivatives having the general formula I | 10-22-2009 |
20110046131 | PURINES AS PKC-THETA INHIBITORS - A chemical genus of purines, which are useful as PKCθ inhibitors, is disclosed. The genus is represented by the formula (I); A representative example is: (II) | 02-24-2011 |
20110218189 | PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS - The present invention relates to a pyrrolo[2,3-d]pyrimidin-2-yl-amine derivative according to formula (I) wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said pyrrolo[2,3-d]pyrimidine-2-ylamine derivatives and to their use in therapy, for instance in the treatment of PKCθ mediated disorders. | 09-08-2011 |
20120015958 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES - The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R | 01-19-2012 |
Patent application number | Description | Published |
20090153873 | Optical Image Measuring Apparatus - Provided is an optical image measuring apparatus capable of obtaining a high-accuracy image without being influenced by a movement of an object to be measured. Flash light is emitted from a xenon lamp ( | 06-18-2009 |
20090153876 | OPTICAL IMAGE MEASUREMENT DEVICE - An optical image measurement device comprises: a light source configured to output a light having low temporal coherence and low spatial coherence; an optical system configured to split the light into a signal light and a reference light and superimpose the signal light having passed through a measured object and the reference light, thereby generating an interference light; a light receiver configured to receive the interference light and output an electric signal; and a forming part configured to form an image of the measured object based on the electric signal, wherein: the light receiver has a light receiving face on which a plurality of light receiving elements are arranged 2-dimensionally; and the optical system projects the interference light onto the light receiving face so that a size of the spatial coherent region of the interference light becomes equal to or larger than a size of the light receiving element. | 06-18-2009 |
20100134802 | OPTICAL IMAGE MEASURING DEVICE - An optical image measurement device | 06-03-2010 |
20130027712 | OPTICAL IMAGING METHOD AND OPTICAL IMAGING APPARATUS - An optical imaging method is provided that can realize, at low cost, the extension of the imaging depth range. An optical imaging apparatus | 01-31-2013 |
20130242309 | OPTICAL IMAGING METHOD AND OPTICAL IMAGING APPARTUS - An optical imaging method in an embodiment includes: a scanning step to scan each of a plurality of A-lines of an object with a signal light while alternately changing the phase difference between the signal light and a reference light to two preset phase differences; a detection step to detect the interference light of the signal light passing through the A-line and the reference light; and an imaging step to generate a complex interference spectrum based on the detection results of the interference lights corresponding to the plurality of A-lines sequentially obtained in the detection step according to the scanning, and form, based on the complex interference spectrum, the tomographic image along the arrangement of the plurality of A-lines in which a complex conjugate artifact is substantially removed. | 09-19-2013 |
20140125988 | OPTICAL IMAGING APPARATUS, OPTICAL IMAGING METHOD, APPARATUS FOR SETTING CHARACTERISTICS OF A LIGHT SOURCE, AND METHOD FOR SETTING CHARACTERISTICS OF A LIGHT SOURCE - An embodiment provides a method for setting the characteristics of the light to be output from a light source unit for optical coherence tomography, using a computer. This method is performed by using relation information in which a representative wavelength, a wavelength range including said representative wavelength, and the light loss amount due to absorption by a medium are related to each other. This method includes the following steps: setting each value of a first parameter and a second parameter among the representative wavelength, the wavelength range, and the light loss amount; acquiring a value of a third parameter among the representative wavelength, the wavelength range, and the light loss amount other than said first parameter and said second parameter based on the set two values and said relation information; and outputting a value of said acquired third parameter. | 05-08-2014 |
20140204386 | IMAGE MEASURING METHOD AND IMAGE MEASURING APPARATUS - [Problem] Image artifacts caused by noises in clock signals are suppressed. | 07-24-2014 |
20150015845 | OPTICAL COHERENCE TOMOGRAPHY WITH DYNAMIC FOCUS SWEEPING AND WINDOWED AVERAGING - During scan capture with an OCT imaging system, the focal plane position can be simultaneously shifted over at least a portion of an image range. As a result, a plurality of image frames respectively corresponding to various focal plane positions is acquired. The image frames can be combined to generate a composite image having suitable resolution throughout the image range, including regions associated with weak-intensity or low-reflectance features. Further, windowed averaging can be performed prior to generation of the composite image so that the composite image incorporates weights given to image data in focus. | 01-15-2015 |
20150204651 | DETECTION OF MISSAMPLED INTERFEROGRAMS IN FREQUENCY DOMAIN OCT WITH A K-CLOCK - Optical coherence tomography light sources can be non-linear and attempts to linearize them can lead to asynchrony between the light source and A-line scans and missampling in the scans causing signal noise. Accordingly, a system and methods are provided herein to detect missampling by obtaining a plurality of interferograms; providing at least two wavenumber reference signals at different wavenumbers, wherein the wavenumber reference signals comprise attenuated or enhanced portions of each of the plurality of interferograms; aligning each of the plurality of interferograms according to one of the at least two wavenumber reference signals; and for each of the plurality of interferograms, identifying an interferogram as missampled if another of the at least two reference signals does not align with a corresponding reference signal in a statistically significant number of the plurality of interferograms. An optical element, for example, an optical notch, may be used to generate the reference signals. | 07-23-2015 |
Patent application number | Description | Published |
20080269722 | Liposuction based on tissue liquefaction - Target tissue may be removed from a subject using a cannula that has an interior cavity and an orifice configured to permit material to enter the cavity. This is accomplished by generating a negative pressure in the cavity so that a portion of the tissue is drawn into the orifice. Fluid is then delivered, via a conduit, so that the fluid exits the conduit within the cavity and impinges against the portion of the tissue that was drawn into the orifice. The fluid is delivered at a pressure and temperature that causes the tissue to soften, liquefy, or gellify. The tissue that has been softened, liquefied, or gellified is then suctioned away. | 10-30-2008 |
20110166552 | LIPOSUCTION BASED ON TISSUE LIQUEFACTION - Target tissue may be removed from a subject using a cannula that has an interior cavity and an orifice configured to permit material to enter the cavity. This is accomplished by generating a negative pressure in the cavity so that a portion of the tissue is drawn into the orifice. Fluid is then delivered, via a conduit, so that the fluid exits the conduit within the cavity and impinges against the portion of the tissue that was drawn into the orifice. The fluid is delivered at a pressure and temperature that causes the tissue to soften, liquefy, or gellify. The tissue that has been softened, liquefied, or gellified is then suctioned away. | 07-07-2011 |
20120277698 | HARVESTING FAT TISSUE USING TISSUE LIQUEFACTION - Target tissue may be removed from a subject using a cannula that has an interior cavity and an orifice configured to permit material to enter the cavity. This is accomplished by generating a negative pressure in the cavity so that a portion of the tissue is drawn into the orifice. Fluid is then delivered, via a conduit, so that the fluid exits the conduit within the cavity and impinges against the portion of the tissue that was drawn into the orifice. The fluid is delivered at a pressure and temperature that causes the tissue to soften, liquefy, or gellify. The tissue that has been softened, liquefied, or gellified is then suctioned away. The matter that was suctioned away is collected, and fat that is suitable for implantation in the subject is extracted from the collected matter. | 11-01-2012 |
Patent application number | Description | Published |
20130011824 | Polymeric Sorbent for Removal of Impurities From Whole Blood and Blood Products - The invention concerns methods of treating blood, blood products or physiologic fluid to maximize shelf life and/or minimizing transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood, blood product or physiologic fluid milieu through use of a sorbent. | 01-10-2013 |
20130195792 | METHOD OF TREATING INFLAMMATION - The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer. | 08-01-2013 |
20130261606 | Harvesting Fat Tissue Using Tissue Liquefaction - Target tissue may be removed from a subject using a cannula that has an interior cavity and an orifice configured to permit material to enter the cavity. This is accomplished by generating a negative pressure in the cavity so that a portion of the tissue is drawn into the orifice. Fluid is then delivered, via a conduit, so that the fluid exits the conduit within the cavity and impinges against the portion of the tissue that was drawn into the orifice. The fluid is delivered at a pressure and temperature that causes the tissue to soften, liquefy, or gellify. The tissue that has been softened, liquefied, or gellified is then suctioned away. The matter that was suctioned away is collected and gravity separated, and fat that is suitable for implantation in the subject is extracted from a selected layer (e.g., the top half) of the supernatant of the gravity-separated matter. | 10-03-2013 |
20140042097 | COMPOSITIONS AND METHODS USEFUL IN SELECTIVELY MODIFYING THE INTERNAL AND EXTERNAL SURFACES OF POROUS POLYMER BEADS - The invention concerns polymer systems comprising at least one polymer with a plurality of pores where the polymer is initially functionalized on substantially all surfaces followed by a stepwise surface specific functionalization such that a different functional group resides on the external or internal pore surface of the bead. The invention also concerns use of such polymer systems in blood, blood product, or physiologic fluid purification. | 02-13-2014 |
20150118673 | POLYMERIC SORBENT FOR REMOVAL OF IMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS - The invention concerns methods of treating stored blood and blood products maximizing shelf life and/or minimizing transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood and blood products milieu through use of a sorbent. | 04-30-2015 |
20150335576 | METHODS OF USING POLYMERS - Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same. | 11-26-2015 |
Patent application number | Description | Published |
20110258939 | METHODS FOR PRODUCING NANOPARTICLES HAVING HIGH DEFECT DENSITY AND USES THEREOF - The disclosed subject matter is directed to a method for producing nanoparticles, as well as the nanoparticles produced by this method. In one embodiment, the nanoparticles produced by the disclosed method have a high defect density. A solution including cerium nitrate hexahydrate is combined with a solution including hexamethylenetetramine to form a combined aqueous solution. After a period of time, the combined aqueous solution is combined with a solution including copper nitrate trihydrate to form a further aqueous solution. The further aqueous solution is then mixed to produce nanoparticles. | 10-27-2011 |
20120028795 | Methods For Producing Nanoparticles Using Palladium Salt And Uses Thereof - The disclosed subject matter is directed to a method for producing nanoparticles, as well as the nanoparticles produced by this method. In one embodiment, the nanoparticles produced by the disclosed method have a high defect density. | 02-02-2012 |
20140130415 | Method And System For Production Of Hydrogen And Carbon Monoxide - A method for preparing a fuel using oxygen-storing compound nanoparticles is provided, in which the nanoparticles is heated at a first temperature to release an amount of oxygen, thereby producing a reduced oxide compound, and the reduced oxide compound is exposed to a gas at a second temperature to produce the fuel. The gas can include carbon dioxide and water vapor, and the fuel can include carbon monoxide and/or hydrogen. The oxygen-storing compound nanoparticles can be nano ceria or nano ceria doped with one or more metals, such as Cu and/or Zr. A system for carrying out the method is also disclosed. | 05-15-2014 |
Patent application number | Description | Published |
20100145048 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 06-10-2010 |
20110033417 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS - The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 02-10-2011 |
20110059958 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS - The present invention provides a compound of Formula (I) | 03-10-2011 |
20110065682 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS - The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. | 03-17-2011 |
20110104110 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 05-05-2011 |
20110117057 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS - The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. | 05-19-2011 |
20110135650 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS - The present invention provides a compound of Formula (I) | 06-09-2011 |
20110165118 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to 3-Heterocyclic Substituted Indole Derivatives, compositions comprising at least one 3-Heterocyclic Substituted Indole Derivative, and methods of using the 3-Heterocyclic Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 07-07-2011 |
20110224137 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I). | 09-15-2011 |
20110224193 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown with this abstract. | 09-15-2011 |
20120136016 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS - The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. | 05-31-2012 |
20130210816 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS - The invention relates to fused-imidazoyl compounds of Formula (I): wherein ring A, R | 08-15-2013 |
20150368269 | Factor IXa Inhibitors - The present invention provides a compound of Formula (I) | 12-24-2015 |
Patent application number | Description | Published |
20090066430 | BATCH-FABRICATED, RF-INTERROGATED, END TRANSITION, CHIP-SCALE ATOMIC CLOCK - A chip scale atomic clock is disclosed that provides a low power atomic time/frequency reference that employs direct RF-interrogation on an end-state transition. The atomic time/frequency reference includes an alkali vapor cell containing alkali atoms, preferably cesium atoms, flex circuits for physically supporting, heating, and thermally isolating the alkali vapor cell, a laser source for pumping alkali atoms within the alkali vapor cell into an end resonance state by applying an optical signal along a first axis, a photodetector for detecting a second optical signal emanating from the alkali vapor cell along the first axis, a pair of RF excitation coils for applying an RF-interrogation signal to the alkali atoms along a second axis perpendicular to the first axis, a pair of bias coils for applying a uniform DC magnetic field along the first axis, and a pair of Zeeman coils for applying a Zeeman interrogation signal to the alkali atoms and oriented and configured to apply a time-varying magnetic field along the second axis through the alkali vapor cell. Another flex circuit is used for physically supporting the laser source, for heating the laser source, and for providing thermal isolation of the laser source. The laser source can be a vertical cavity surface emitting laser (VSCEL). The bias coils can be Helmholtz coils. | 03-12-2009 |
20090152533 | INCREASING THE EXTERNAL EFFICIENCY OF LIGHT EMITTING DIODES - The present disclosure relates to increasing the external efficiency of light emitting diodes, and specifically to increasing the outcoupling of light from an organic light emitting diode utilizing a diffraction grating. | 06-18-2009 |
20110168236 | PORTABLE PHOTOVOLTAICS WITH SCALABLE INTEGRATED CONCENTRATOR OF LIGHT ENERGY - A luminescent solar concentrator (LSC) for receiving electromagnetic radiation of at least a first wavelength is disclosed. The LSC includes a core layer. A lower clad layer substantially underlies the core layer. At least one photovoltaic (PV) cell is partially embedded in at least one of the core layer and the lower clad layer. At least one dye layer substantially overlies the core layer. The at least one dye layer has embedded therein at least one absorption dipole and at least one emission dipole, the at least one emission dipole being coupled to the at least one absorption dipole. The at least one absorption dipole is configured to absorb the electromagnetic radiation of at least a first wavelength incident from any direction and the at least one emission dipole is configured to emit electromagnetic radiation of at least a second wavelength substantially within at least one of the core layer and the lower clad layer so that the electromagnetic radiation of at least a second wavelength is at least partially absorbed by the at least one PV cell. The at least one absorption dipole is coupled to the at least one emission dipole by Forster resonant energy transfer (FRET). | 07-14-2011 |
20110274130 | SINGLE RIDGE N-P-N DIODE LASER - The present disclosure relates to a diode laser and a method for producing the same. In one embodiment, the diode laser, comprises a passive pedestal layer structure, an active ridge layer structure positioned over the passive pedestal layer structure, a p-contact contacting a top side of the active ridge layer structure, a first n-contact disposed on a first side of the active ridge layer structure, a second n-contact disposed on a second side of the active ridge layer structure and, an n-final-metal layer connecting the first n-contact metal and the second n-contact metal, wherein the n-final-metal layer is continuous over the active ridge layer structure. | 11-10-2011 |